Arsinothricin Inhibits Plasmodium falciparum Proliferation in Blood and Blocks Parasite Transmission to Mosquitoes
Microorganisms · 03.05.2023 · 11 (5) · 1195
DOI: 10.3390/microorganisms11051195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 03.05.2023. Verfasst von Masafumi Yoshinaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St., Miami, FL …. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIH/NIAID.
Abstract (Originalsprache)
Malaria, caused by Plasmodium protozoal parasites, remains a leading cause of morbidity and mortality. The Plasmodium parasite has a complex life cycle, with asexual and sexual forms in humans and Anopheles mosquitoes. Most antimalarials target only the symptomatic asexual blood stage. However, to ensure malaria eradication, new drugs with efficacy at multiple stages of the life cycle are necessary. We previously demonstrated that arsinothricin (AST), a newly discovered organoarsenical natural product, is a potent broad-spectrum antibiotic that inhibits the growth of various prokaryotic pathogens. Here, we report that AST is an effective multi-stage antimalarial. AST is a nonproteinogenic amino acid analog of glutamate that inhibits prokaryotic glutamine synthetase (GS). Phylogenetic analysis shows that Plasmodium GS, which is expressed throughout all stages of the parasite life cycle, is more closely related to prokaryotic GS than eukaryotic GS. AST potently inhibits Plasmodium GS, while it is less effective on human GS. Notably, AST effectively inhibits both Plasmodium erythrocytic proliferation and parasite transmission to mosquitoes. In contrast, AST is relatively nontoxic to a number of human cell lines, suggesting that AST is selective against malaria pathogens, with little negative effect on the human host. We propose that AST is a promising lead compound for developing a new class of multi-stage antimalarials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St., Miami, FL 33199, USA.
- Department of Biological Sciences, College of Arts, Sciences & Education, Florida International University, 11200 SW 8th St., Miami, FL 33199, USA.
- Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA.
ORCID-Profile: Masafumi Yoshinaga, Barry P Rosen, Jun Li
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH/NIAID
- NIH/NIGMS
Zitieren
APA
Yoshinaga, M., Niu, G., Yoshinaga-Sakurai, K., Nadar, V. S., Wang, X., Rosen, B. P., & Li, J. (2023). Arsinothricin Inhibits Plasmodium falciparum Proliferation in Blood and Blocks Parasite Transmission to Mosquitoes. Microorganisms, 11(5), 1195. https://doi.org/10.3390/microorganisms11051195
Vancouver
Yoshinaga M, Niu G, Yoshinaga-Sakurai K, Nadar VS, Wang X, Rosen BP, et al. Arsinothricin Inhibits Plasmodium falciparum Proliferation in Blood and Blocks Parasite Transmission to Mosquitoes. Microorganisms. 2023;11(5):1195. doi:10.3390/microorganisms11051195
BibTeX
@article{Yoshinaga2023,
author = {Yoshinaga, Masafumi and Niu, Guodong and Yoshinaga-Sakurai, Kunie and Nadar, Venkadesh S and Wang, Xiaohong and Rosen, Barry P and Li, Jun},
title = {Arsinothricin Inhibits Plasmodium falciparum Proliferation in Blood and Blocks Parasite Transmission to Mosquitoes},
journal = {Microorganisms},
year = {2023},
volume = {11},
number = {5},
pages = {1195},
doi = {10.3390/microorganisms11051195}
}
EUVIMED